Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PSTV Plus Therapeutics
0.402-0.008-1.95%
Close
02/03 16:00 ET
0.4020.0000.00%
Post Mkt Price 02/03 19:46 ET
High
0.430
Open
0.415
Turnover
124.88K
Low
0.390
Pre Close
0.410
Volume
303.75K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersMagenta Therapeutics (NASDAQ:MGTA) stock rose 41.3% to $0.8 during Thursday's after-market session. Trading volume for this security closed at 2.9 million, accounting for 164.9% of its average
Plus Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort
Plus Therapeutics Has Completed Of Enrollment In Cohort 2 Of The Respect-LM Phase 1/2a Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases
The company said the next steps, following the Data and Safety Monitoring Board review anticipated next month, will be completing enrollment in Phase 1/Part A, followed by a meeting with the FDA to co
Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Up 39.7% in January
Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Rating) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 402,600 shares, a growth o
Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Large Drop in Short Interest
Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Rating) saw a large drop in short interest in December. As of December 30th, there was short interest totalling 288,200 shares, a drop of 31.9% from the De
Plus Therapeutics (PSTV) Receives a Buy From Maxim Group
Plus Therapeutics' Phase 2b Trial of Rhenium to Treat Recurrent Glioblastoma Doses First Patient
08:02 AM EST, 01/18/2023 (MT Newswires) -- Plus Therapeutics (PSTV) said Wednesday that the first patient has been dosed in a Phase 2b dose expansion clinical trial evaluating rhenium obisbemeda to tr
Plus Therapeutics: 1st Patient Dosed in Rhenium Study Obisbemeda to Treat GBM
Plus Therapeutics Announces First Patient Dosed In ReSPECT-GBM Phase 2b Trial Of Rhenium (186Re) Obisbemeda For Treatment Of Recurrent Glioblastoma
Plus Therapeutics Announces First Patient Dosed In ReSPECT-GBM Phase 2b Trial Of Rhenium (186Re) Obisbemeda For Treatment Of Recurrent Glioblastoma
Why Geron Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
Gainers Vyant Bio, Inc. (NASDAQ:VYNT) shares rose 110.4% to $1.62 in pre-market trading after the company said it has engaged LifeSci Capital as its advisor to explore strategic alternatives.Humanigen
Company Overview
More
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
CEO： Dr. Marc H. Hedrick,M.D.
Market： NASDAQ
Listing Date： 12/19/2005
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet